96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation

Valentina Di Cristo,Fulvio Adorni,Renato Maserati,Marco Annovazzi Lodi,Giuseppe Bruno,Paolo Maggi,Anna Volpe,Paola Vitiello,C. Abeli,Stefano Bonora,Micol Ferrara,Maria Vittoria Cossu,Maria Letizia Oreni,Elisa Colella,Stefano Rusconi

96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation

2020

Valentina Di Cristo
Fulvio Adorni
Renato Maserati
Marco Annovazzi Lodi
Giuseppe Bruno
Paolo Maggi
Anna Volpe
Paola Vitiello
C. Abeli
Stefano Bonora
Micol Ferrara
Maria Vittoria Cossu
Maria Letizia Oreni
Elisa Colella
Stefano Rusconi

Antiretroviral therapies have been tested with the goal of maintaining virological suppression with a particular attention in limiting drug-related toxicity. With this aim we designed the DUAL stud...

Keywords:

Oncology
Toxicity
Darunavir
Internal medicine
Darunavir+Ritonavir
Rilpivirine
Medicine
Limiting
dual therapy
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations